Urgent need to address infectious diseases due to immunosuppressive therapies.
作者信息
Chastain Daniel B, Stover Kayla R
机构信息
Clinical Associate Professor, University of Georgia College of Pharmacy, 1000 Jefferson Street, Albany, GA 31701, USA.
Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, MS, USA.
出版信息
Ther Adv Infect Dis. 2023 Apr 29;10:20499361231168512. doi: 10.1177/20499361231168512. eCollection 2023 Jan-Dec.
Abstract
摘要
相似文献
1
Urgent need to address infectious diseases due to immunosuppressive therapies.迫切需要应对免疫抑制疗法导致的传染病。
Ther Adv Infect Dis. 2023 Apr 29;10:20499361231168512. doi: 10.1177/20499361231168512. eCollection 2023 Jan-Dec.
2
Infectious complications in SLE after immunosuppressive therapies.免疫抑制治疗后系统性红斑狼疮的感染性并发症。
Curr Opin Rheumatol. 2003 Sep;15(5):528-34. doi: 10.1097/00002281-200309000-00002.
3
[Infectious complications due to immunosuppression in organ transplant patients].[器官移植患者免疫抑制导致的感染性并发症]
Rev Prat. 2007 Oct 15;57(15):1677-86.
4
Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression".免疫抑制剂与移植感染风险：管理“免疫抑制净状态”。
Clin Infect Dis. 2021 Oct 5;73(7):e1302-e1317. doi: 10.1093/cid/ciaa1189.
5
Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis.卡氏肺孢子虫肺炎：韦格纳肉芽肿病患者免疫抑制治疗的主要并发症。
Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):795-9. doi: 10.1164/ajrccm/151.3_Pt_1.795.
6
[Functional immunoassays in the setting of infectious risk and immunosuppressive therapy of non-HIV immunocompromised patients].[非HIV免疫功能低下患者感染风险及免疫抑制治疗背景下的功能性免疫测定]
Rev Med Interne. 2020 Aug;41(8):545-551. doi: 10.1016/j.revmed.2020.04.008. Epub 2020 Jul 3.
7
Opportunistic infections--coming to the limits of immunosuppression?机会性感染——是否即将达到免疫抑制的极限？
Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a015669. doi: 10.1101/cshperspect.a015669.
8
9
Antibody immunosuppressive therapy in solid-organ transplant: Part I.实体器官移植中的抗体免疫抑制治疗：第一部分。
MAbs. 2010 Mar-Apr;2(2):148-56. doi: 10.4161/mabs.2.2.11159.
10
Adverse Effects of Immunosuppression: Infections.免疫抑制的不良反应：感染。
Handb Exp Pharmacol. 2022;272:287-314. doi: 10.1007/164_2021_550.
引用本文的文献
1
Evaluating impacts of the trichloroethylene metabolite -(1,2-dichlorovyinyl)-L-cysteine on transcriptomic responses and cytokine release in a macrophage model: implications for pregnancy outcomes.评估三氯乙烯代谢物 -（1,2 - 二氯乙烯基）-L - 半胱氨酸对巨噬细胞模型中转录组反应和细胞因子释放的影响：对妊娠结局的影响
J Immunotoxicol. 2025 Dec;22(1):2522041. doi: 10.1080/1547691X.2025.2522041. Epub 2025 Jul 3.
2
Comparing the effectiveness of different vaccines in individuals with and without autoimmune diseases: a study protocol for a target trial emulation.比较不同疫苗在患有和未患自身免疫性疾病个体中的有效性：一项目标试验模拟的研究方案。
Front Public Health. 2025 May 26;13:1583434. doi: 10.3389/fpubh.2025.1583434. eCollection 2025.
3
The impact of climate change on the epidemiology of fungal infections: implications for diagnosis, treatment, and public health strategies.气候变化对真菌感染流行病学的影响：对诊断、治疗及公共卫生策略的启示
Ther Adv Infect Dis. 2025 Feb 11;12:20499361251313841. doi: 10.1177/20499361251313841. eCollection 2025 Jan-Dec.
4
Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases.自身免疫性风湿性疾病发病机制中的分子模拟
J Transl Autoimmun. 2025 Jan 7;10:100269. doi: 10.1016/j.jtauto.2025.100269. eCollection 2025 Jun.
5
Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease.基于水凝胶的方法靶向自身免疫性疾病潜在的过敏机制。
Adv Drug Deliv Rev. 2024 Sep;212:115395. doi: 10.1016/j.addr.2024.115395. Epub 2024 Jul 14.
6
High-dose amphotericin: yay or nay? A case series and literature review.大剂量两性霉素：支持还是反对？病例系列及文献综述。
Drugs Context. 2024 Jan 15;13. doi: 10.7573/dic.2023-9-1. eCollection 2024.
本文引用的文献
1
Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019.2018-2019 年美国商业保险成年人中免疫抑制药物使用的流行率。
JAMA Netw Open. 2021 May 3;4(5):e214920. doi: 10.1001/jamanetworkopen.2021.4920.
2
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).ESCMID 研究组对免疫受损宿主感染（ESGICH）共识文件：靶向和生物治疗的安全性：传染病观点（可溶性免疫效应分子 [I]：抗肿瘤坏死因子-α制剂）
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6.
3
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).欧洲临床微生物学和传染病学会（ESCMID）感染宿主研究组（ESGICH）关于靶向和生物治疗安全性的共识文件：传染病学视角（细胞内信号通路：酪氨酸激酶和 mTOR 抑制剂）。
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70. doi: 10.1016/j.cmi.2018.02.009. Epub 2018 Feb 16.
4
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).欧洲临床微生物学和传染病学会（ESCMID）感染宿主研究组（ESGICH）关于靶向和生物治疗安全性的共识文件：传染病学视角（靶向淋巴细胞表面抗原的药物 [I]：CD19、CD20 和 CD52）。
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S71-S82. doi: 10.1016/j.cmi.2018.02.003. Epub 2018 Feb 12.
5
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).ESCMID 研究组（ESGICH）对有合并症宿主感染的共识文件：靶向和生物治疗的安全性：传染病学视角（可溶性免疫效应分子[II]：针对白细胞介素、免疫球蛋白和补体因子的药物）。
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S21-S40. doi: 10.1016/j.cmi.2018.02.002. Epub 2018 Feb 12.
6
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).ESCMID 研究组（ESGICH）关于有合并症宿主感染的共识文件：靶向和生物治疗的安全性：传染病视角（引言）。
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S2-S9. doi: 10.1016/j.cmi.2018.01.029. Epub 2018 Feb 7.
7
Overview of Infections in the Immunocompromised Host.免疫功能低下宿主的感染概述。
Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.DMIH2-0026-2016.
8
Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?甲氨蝶呤、类风湿关节炎与感染风险：证据有哪些？
Rheumatology (Oxford). 2009 Aug;48(8):867-71. doi: 10.1093/rheumatology/kep101. Epub 2009 May 15.
9
An overview of the immune system.免疫系统概述。
Lancet. 2001 Jun 2;357(9270):1777-89. doi: 10.1016/S0140-6736(00)04904-7.
10
Glucocorticosteroid therapy: mechanisms of action and clinical considerations.糖皮质激素疗法：作用机制与临床考量
Ann Intern Med. 1976 Mar;84(3):304-15. doi: 10.7326/0003-4819-84-3-304.
Zotero 插件